IlluminOss receives new patents for bone stabilization system

IlluminOss receives new patents for bone stabilization system

 
IlluminOss Medical announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for instruments used in the company’s Photodynamic Bone Stabilization System.

The minimally invasive Photodynamic Bone Stabilization System stabilizes bone fractures or prevents impending fractures through a percutaneous fracture fixation system that can be implanted for stand-alone primary fixation or in combination with screws or plates. The system is customized fitted for each patient’s specific anatomy providing rotational and torsional stability to the fracture.

IlluminOss Medical Secures $28 Million Series C Financing for Minimally Invasive Bone Fracture Repair

 

East Providence, RI - September 27, 2012 – IlluminOss Medical, Inc., the company pioneering photodynamic orthopedic implants, announced today that it has secured a $28 million Series C round of venture capital financing. Tekla Capital Management, the registered investment advisor to H&Q Life Sciences Investors and H&Q Healthcare Investors (together, the “H&Q Funds”), based in Boston, MA, and Life Sciences Partners, a global healthcare and life science investment firm based in Amsterdam, Munich and Boston, co-led the round with the full participation of the existing investors Foundation Medical Partners, Mieza Capital and New Leaf Venture Partners. Four additional new investors also joined this latest round, including SR One, Excel Venture Management, Pappas Ventures, and the Slater Technology Fund.

Click here to read the full release.

IlluminOss Press Release - IlluminOss Medical Secures $28 Million Series C Financing for Minimally Invasive Bone Fracture Repair

East Providence, RI - September 27, 2012 – IlluminOss Medical, Inc., the company pioneering photodynamic orthopedic implants, announced today that it has secured a $28 million Series C round of venture capital financing. Tekla Capital Management, the registered investment advisor to H&Q Life Sciences Investors and H&Q Healthcare Investors (together, the “H&Q Funds”), based in Boston, MA, and Life Sciences Partners, a global healthcare and life science investment firm based in Amsterdam, Munich and Boston, co-led the round with the full participation of the existing investors Foundation Medical Partners, Mieza Capital and New Leaf Venture Partners. Four additional new investors also joined this latest round, including SR One, Excel Venture Management, Pappas Ventures, and the Slater Technology Fund.

Click here to read the full release.